Cancer patients are a boon! Baiyang hand-in-hand medicine, tumor radiotherapy to have a big action!

(Health Times reporter Zhang He) recently, Baiyang Pharmaceutical Group's Baiyang Intelligent Technology and Medical University jointly announced that the two sides signed a strategic cooperation agreement to jointly promote the use of medical artificial intelligence in the field of tumor treatment, to provide patients with personalized, standardized treatment options.
65%-80% of patients in the United States use radiation therapy, China only 30%
in the tumor of the three major treatment methods, the treatment market can be initially divided into surgical treatment, radiation therapy and chemotherapy. About 70 percent of these cancer patients require radiation therapy during treatment, and about 40 percent of cancers can be treated with radiation. The role and status of radiation therapy in tumor treatment is becoming more and more prominent, and it has become one of the main means of treating malignant tumors.Compared with developed countries such as the United States, the
, China's cancer treatment means show a high proportion of drugs, low surgical rate, low radiotherapy rate characteristics. According to 2015 data, the proportion of cancer treatments in China is much higher than in the United States, while the proportion of radiation therapy in the United States is much higher than that of China. At least 65% to 80% of patients in the U.S. use radiotherapy during treatment, compared with 30% in China.
radiotherapy with WfO artificial intelligence solutions
Fu Gang, chairman of Baiyang Pharmaceutical Group, said: "Artificial intelligence is only a component, integrated into various medical scenarios to form a holistic solution to release value, Watson for oncology (tumor solutions) in the radiotherapy time management, MDT consultation communication, check room doctor training and patient second diagnosis opinion and other scenarios reflect the value of significant optimization of efficiency." "
compared with the mature market, China's radiotherapy market there is a large gap, China has only 1.57 radiotherapy equipment per million people, 12.4 units in the United States. As far as radiotherapy itself is concerned, because there are large individual differences in sensitivity of patients with malignant tumors to radiotherapy, many times, the standard radiation dose given to patients may be over-treatment for some patients, and some patients may have problems with inadequate treatment intensity. The introduction of WfO artificial intelligence solution is an important basis for the realization of precision and personalized radiotherapy for tumor patients.
WfO has stored and studied a large number of MSKCC tumor cases, more than 300 medical journals, more than 250 oncology monographs, and more than 15 million paper research data, as well as NCCN-based cancer treatment guidelines and MSKCC multi-year clinical experience in cancer treatment. Currently covering 13 types of tumors, compared with the treatment options given by the top expert group, WfO's treatment plan has reached more than 90% compliance, and has been in China's 22 provinces and 39 cities in 68 medical institutions, successfully for nearly 20,000 cancer patients to provide standardized, personalized treatment programs."I am very pleased to be able to work with Baiyang Intelligent Technology to introduce and develop the application of The Incentfors For Oncology in the Chinese market, which will help doctors make decisions, and believe that the cooperation will comprehensively promote the development of Chinese medicine towards "precision," "personalization" and "intelligence" for the benefit of more Chinese cancer patients," said Yu Anming, executive vice president and president of medical companies in China.
"
.